To read the full story
Related Article
- Astellas’ Gastric Cancer Med Vyloy Approved in US after Re-Filing
October 22, 2024
- FDA Accepts Re-Filing of Astellas’ Gastric Cancer Med for Review
June 3, 2024
- Japan Panel Clears Astellas’ Gastric Cancer Med for Approval after FDA Rejection
March 5, 2024
- Astellas’ 1st-in-Class Gastric Cancer Med Bags Priority Review in US
July 7, 2023
- Astellas Files Zolbetuximab for CLDN18.2-Positive Gastric Cancer in Japan
June 12, 2023
- Detailed Data Out for PIII Zolbetuximab Study in 1st-Line Gastric Cancer: Astellas
March 23, 2023
- Astellas’s Zolbetuximab Makes Marks in Another PIII Gastric Cancer Study
December 19, 2022
- Astellas’s Zolbetuximab Hits Goals in PIII Gastric Cancer Trial
November 18, 2022
BUSINESS
- Shionogi, Cilcare Ink Research Collab on Novel Hearing Loss Drugs
May 12, 2025
- Canaglu Now Available in Thailand: Mitsubishi Tanabe
May 12, 2025
- Keytruda Tops Japan Drug Sales Ranking for 19th Month: Encise
May 12, 2025
- Japan Ethical Drug Sales Up 5.2% in March: Crecon
May 12, 2025
- Otsuka, Keio Join Hands to Facilitate “Social Implementation” of Psychedelics
May 12, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…